Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Public ClinicalTrials.gov record NCT05579366. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors
Study identification
- NCT ID
- NCT05579366
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Genmab
- Industry
- Enrollment
- 764 participants
Conditions and interventions
Conditions
- Breast Adenocarcinoma
- Endometrial Cancer
- Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)
- Fallopian Tube Cancer
- High Grade Epithelial Ovarian Cancer
- High Grade Serous Ovarian Cancer
- Hormone Receptor-positive/Her2 Negative Breast Cancer
- Mesothelioma
- Non-small Cell Lung Cancer
- Platinum Sensitive Ovarian Cancer (PSOC)
- Platinum-resistant Ovarian Cancer (PROC)
- Primary Peritoneal Carcinoma
- Primary Refractory Ovarian Cancer
- Triple Negative Breast Cancer
- Uterine Cancer
Interventions
- Bevacizumab Drug
- Carboplatin Drug
- Pembrolizumab Drug
- Rina-S Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 6, 2022
- Primary completion
- Jun 30, 2027
- Completion
- Sep 30, 2027
- Last update posted
- Apr 6, 2026
2022 – 2027
United States locations
- U.S. sites
- 37
- U.S. states
- 20
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USOR HonorHealth | Phoenix | Arizona | 85016 | Recruiting |
| USOR Arizona Oncology Associates | Tucson | Arizona | 85711 | Recruiting |
| University of California Los Angeles Medical Center | Los Angeles | California | 90095 | Recruiting |
| University of California, San Diego; Moores Cancer Center | San Diego | California | 92093 | Recruiting |
| USOR Sansum Clinic | Santa Barbara | California | 93105 | Recruiting |
| Providence Medical Foundation | Santa Rosa | California | 95403 | Recruiting |
| USOR Florida Cancer Specialists South | Fort Myers | Florida | 33908 | Recruiting |
| USOR Florida Cancer Specialists North | St. Petersburg | Florida | 33709 | Recruiting |
| USOR Florida Cancer Specialists East | West Palm Beach | Florida | 33401 | Recruiting |
| Augusta University Georgia Cancer Center | Augusta | Georgia | 30912 | Recruiting |
| University of Kansas Medical Center (KUMC) | Westwood | Kansas | 66205 | Recruiting |
| USOR Maryland Oncology Hematology | Rockville | Maryland | 20850 | Recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Recruiting |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| Karmanos Cancer Institute | Detroit | Michigan | 48085 | Recruiting |
| START Midwest | Grand Rapids | Michigan | 49503 | Recruiting |
| USOR Minnesota Oncology Hematology | Maplewood | Minnesota | 55109 | Recruiting |
| MD Anderson Cancer Center at Cooper- Two Cooper Plaza | Camden | New Jersey | 08103 | Recruiting |
| Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute | Columbus | Ohio | 43210 | Recruiting |
| University of Oklahoma - Health Sciences Center | Oklahoma City | Oklahoma | 73104 | Recruiting |
| USOR Oncology Associates of Oregon, P.C. | Eugene | Oregon | 97401 | Recruiting |
| Compass Oncology - Rose Quarter | Portland | Oregon | 97227 | Recruiting |
| USOR Alliance Cancer Specialist | Doylestown | Pennsylvania | 18901 | Recruiting |
| Allegheny Health Network | Pittsburgh | Pennsylvania | 15224 | Recruiting |
| Women and Infants Hospital of Rhode Island | Providence | Rhode Island | 02905 | Recruiting |
| Sarah Cannon Research Institute at Tennessee Oncology | Nashville | Tennessee | 37203 | Recruiting |
| Tennessee Oncology | Nashville | Tennessee | 37203 | Recruiting |
| USOR Texas Oncology | Abilene | Texas | 79606 | Recruiting |
| Texas Oncology - Central / South Texas | Austin | Texas | 78758 | Recruiting |
| Mary Crowley Cancer Research | Dallas | Texas | 75521 | Recruiting |
| USOR Texas Oncology | Fort Worth | Texas | 76104 | Recruiting |
| Texas Oncology - Northeast TX | Tyler | Texas | 75702 | Recruiting |
| USOR Texas Oncology Gulf Coast | Woodland | Texas | 77380 | Recruiting |
| START Mountain Region | West Valley City | Utah | 84119 | Recruiting |
| USOR Virginia Cancer Specialists | Fairfax | Virginia | 22031 | Recruiting |
| USOR Virginia Oncology Associates | Norfolk | Virginia | 23502 | Recruiting |
| Swedish Cancer Institute | Seattle | Washington | 98104 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05579366, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 6, 2026 · Synced May 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05579366 live on ClinicalTrials.gov.